--- schema_version: "secwatch.filing_event.v1" accession: "0001437749-24-001524" form_type: "8-K" ticker: null cik: "0001513818" company_name: "Aravive, Inc." filed_at: "2024-01-17T23:59:59+00:00" generated_at: "2026-06-06T22:33:03.731007+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Aravive to liquidate, delist from Nasdaq, and terminate CEO and CFO ## Summary - Board approved transfer of all assets via assignment for the benefit of creditors on Jan 12, 2024. - Company will voluntarily delist from Nasdaq; Form 25 to be filed Jan 29, effective ~Feb 8. - Deregistration with SEC via Form 15 expected ~Feb 8; company has <300 record holders. - CEO Gail McIntyre and CFO Rudy Howard terminated Jan 17; entered separation agreements with severance. - All five directors resigned; dissolution via Certificate of Dissolution filed with Delaware ~Jan 29. ## SEC filing metadata - accession: 0001437749-24-001524 - form_type: 8-K - cik: 0001513818 - company_name: Aravive, Inc. - filed_at: 2024-01-17T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.01, 2.01, 3.01, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/arav20240116c_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001437749-24-001524 - JSON: https://secwatch.observer/filing/0001437749-24-001524.json - Plain text: https://secwatch.observer/filing/0001437749-24-001524.txt ## Key facts - Executive change Dr. Eshelman resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: (ii) Dr. Eshelman and Dr. McIntyre each provided notice of their decision to resign from the Board and all committees thereof, effective immediately after the filing of the Form 15 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Rudy C. Howard was terminated as Chief Financial Officer at Aravive, Inc.. - Action: terminated - Role: Chief Financial Officer source text: the Company terminated the employment of each of Gail McIntrye, Ph.D., the Company’s Chief Executive Officer and Rudy C. Howard, the Company’s Chief Financial Officer, effective as of January 17, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Gail McIntyre was terminated as Chief Executive Officer at Aravive, Inc.. - Action: terminated - Role: Chief Executive Officer source text: the Company terminated the employment of each of Gail McIntrye, Ph.D., the Company’s Chief Executive Officer and Rudy C. Howard, the Company’s Chief Financial Officer, effective as of January 17, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Michael W. Rogers resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Amato Giaccia resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Gail McIntyre was appointed as Secretary and Authorized Officer at Aravive, Inc.. - Action: appointed - Role: Secretary and Authorized Officer source text: Dr. McIntyre’s Separation Agreement also provides that Dr. McIntyre will provide consulting services to the Company, at no further cost, as may be required in connection with the liquidation of the Company and that in such capacity, Dr. McIntyre shall serve as the Company’s Secretary and Authorized Officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Peter T.C. Ho resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change John A. Hohneker resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Sigurd C. Kirk resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Executive change Gail McIntyre resigned as Director at Aravive, Inc.. - Action: resigned - Role: Director source text: (ii) Dr. Eshelman and Dr. McIntyre each provided notice of their decision to resign from the Board and all committees thereof, effective immediately after the filing of the Form 15 evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - M&A Transactions Aravive, Inc. completed a disposition involving Aravive (assignment for the benefit of creditors), LLC (closed 2024-01-17). - Action: disposition - Counterparty: Aravive (assignment for the benefit of creditors), LLC - Closing: 2024-01-17 source text: y’s assets through an assignment for the benefit of creditors was in the best interest of the Company, and (ii) authorized the Company to enter into a general assignment for the benefit of creditors (the “Assignment Agreement”), by and between the Company and Aravive (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”), which provides for the transfer of all or substantially all of the Company’s assets to the Assignee (the “Assignment”). evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm - Material Agreements Aravive, Inc. entered into Assignment Agreement with Aravive (assignment for the benefit of creditors), LLC (effective 2024-01-17). - Action: entry - Counterparty: Aravive (assignment for the benefit of creditors), LLC - Effective: 2024-01-17 source text: the transfer of all or substantially all of the Company’s assets through an assignment for the benefit of creditors was in the best interest of the Company, and (ii) authorized the Company to enter into a general assignment for the benefit of creditors (the “Assignment Agreement”), by and between the Company and Aravive (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”), which provides for the transfer of all or substantially all of the Company’s assets to the Assignee (the “Assignment”). evidence_url: https://www.sec.gov/Archives/edgar/data/1513818/000143774924001524/0001437749-24-001524-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.